NCT01775124 - Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) | Biotech Hunter

Enrollment

332

Participants

Timeline

Start Date

February 22, 2013

Primary Completion Date

November 23, 2015

Study Completion Date

November 23, 2015

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab

Intravitreal injections of 0.5 mg Ranibizumab

Trial Locations (23)

100044

Novartis Investigative Site, Beijing

100176

Novartis Investigative Site, Beijing

100191

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

110011

Novartis Investigative Site, Shenyang

150001

Novartis Investigative Site, Harbin

200031

Novartis Investigative Site, Shanghai

200080

Novartis Investigative Site, Shanghai

200092

Novartis Investigative Site, Shanghai

210029

Novartis Investigative Site, Nanjing

300020

Novartis Investigative Site, Tianjin

300070

Novartis Investigative Site, Tianjin

325027

Novartis Investigative Site, Wenzhou

330006

Novartis Investigative Site, Nanchang

400038

Novartis Investigative Site, Chongqing

400042

Novartis Investigative Site, Chongqing

410011

Novartis Investigative Site, Changsha

430060

Novartis Investigative Site, Wuhan

430070

Novartis Investigative Site, Wuhan

610041

Novartis Investigative Site, Chengdu

730030

Novartis Investigative Site, Lanzhou

2666000

Novartis Investigative Site, Qingdao

030002

Novartis Investigative Site, Taiyuan